olinvacimab: Clinical Trials

6 trials of olinvacimab, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

2 completed, 2 terminated, 2 unknown. 3 Phase 1, 3 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 13Unknown 2, Completed 1
Phase 23Terminated 2, Completed 1

Follow olinvacimab: new trials by email Literature Review of olinvacimab trials Research Report on olinvacimab

Trials newest first · largest first

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Olinvacimab With Pembrolizumab in Patients With mTNBC
Olinvacimab - Metastatic Triple-Negative Breast Cancer
Phase 2TerminatedPharmAbcine192021-09-302025-12-30
TTAC-0001 Phase II Trial With Recurrent Glioblastoma Progressed on Bevacizumab
TTAC-0001 - Recurrent Glioblastoma
Phase 2TerminatedPharmAbcine192019-11-132022-08-18
TTAC-0001 and Pembrolizumab Combination phase1b Trial in Recurrent Glioblastoma
TTAC-0001 and pembrolizumab combination - Recurrent Glioblastoma
Phase 1UnknownPharmAbcine92019-01-162022-08-17
TTAC-0001 and Pembrolizumab Phase Ib Combination Trial in Metastatic Triple-negative Breast Cancer
TTAC-0001 and pembrolizumab combination - Triple Negative Breast Cancer
Phase 1UnknownPharmAbcine112019-01-032022-08-17
Trial to Evaluate the Safety of TTAC-0001(Tanibirumab) in Recurrent Glioblastoma
TTAC-0001 - Recurrent Glioblastoma
Phase 2CompletedPharmAbcine122016-02-042021-01-27
Phase I Trial of Tanibirumab in Advanced or Metastatic Cancer
Tanibirumab - Advanced Cancer, Metastatic Cancer
Phase 1CompletedPharmAbcine262011-11-012014-01-29

Conditions studied

Glioblastoma (3)  ·  Triple Negative Breast Neoplasms (2)  ·  Neoplasm Metastasis (1)

Sponsors

PharmAbcine (6)

Countries

Australia (4)  ·  South Korea (1)  ·  United States (1)

Top investigators

Brenton Seidl, Ph.D, MD (1)  ·  Claire Beecroft, Ph.D, MD (1)  ·  Daphne Day, Ph.D, MD (1)  ·  Dhanusha Sabanathan, Ph.D, MD (1)  ·  Young Seok Park, MD, PhD (1)